Abivax Slides as Investors Continue to Weigh Obefazimod Safety Questions

Abivax (ABVX) is down 14.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor caution after the company’s June 1 Phase 3 maintenance update for obefazimod in ulcerative colitis. While the efficacy results were strong, the market has remained focused on unresolved safety debate around the dataset, and with no fresh company announcement visible today, this looks more like follow-through selling than a brand-new catalyst.

Details:

Abivax said both the 25 mg and 50 mg obefazimod arms met the primary endpoint in the Phase 3 ABTECT maintenance trial, with remission rates well above placebo at Week 44.

Despite the positive topline efficacy, investors have been digesting safety-related concerns tied to the broader readout, which has kept sentiment volatile through June.

The company’s recent materials still point to a planned late-2026 U.S. filing for obefazimod in ulcerative colitis, so the stock appears to be trading on risk reassessment rather than on a change to the regulatory timeline.

Abivax also completed a $45 million ADS offering in May tied to a royalty-certificate repurchase, leaving dilution and capital structure in the background as additional factors traders may still be considering.

Sources:

Abivax, BioPharma Dive, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABVX Hedge Fund Activity

We have seen 159 institutional investors add shares of $ABVX stock to their portfolio, and 132 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

POINT72 ASSET MANAGEMENT, L.P. removed 1,771,418 shares (-73.5%) from their portfolio in Q1 2026, for an estimated $197,247,394
MORGAN STANLEY removed 1,447,036 shares (-45.9%) from their portfolio in Q1 2026, for an estimated $161,127,458
DEUTSCHE BANK AG\ removed 764,899 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $85,171,503
FAIRMOUNT FUNDS MANAGEMENT LLC removed 713,434 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $96,210,142
PARADIGM BIOCAPITAL ADVISORS LP removed 645,000 shares (-45.5%) from their portfolio in Q1 2026, for an estimated $71,820,750
TCG CROSSOVER MANAGEMENT, LLC removed 630,511 shares (-8.9%) from their portfolio in Q1 2026, for an estimated $70,207,399
CORMORANT ASSET MANAGEMENT, LP removed 590,000 shares (-43.7%) from their portfolio in Q1 2026, for an estimated $65,696,500

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABVX Analyst Ratings

Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/25/2026

To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.

$ABVX Price Targets

Multiple analysts have issued price targets for $ABVX recently. We have seen 7 analysts offer price targets for $ABVX in the last 6 months, with a median target of $135.0.

Here are some recent targets:

Julian Harrison from BTIG set a target price of $150.0 on 06/16/2026
David Nierengarten from Wedbush set a target price of $90.0 on 06/02/2026
Jason N. Butler from Citizens set a target price of $187.0 on 06/02/2026
Faisal Khurshid from Jefferies set a target price of $90.0 on 06/02/2026
Judah Frommer from Morgan Stanley set a target price of $132.0 on 06/02/2026
Gregory Renza from Truist Securities set a target price of $135.0 on 06/02/2026
Etzer Darout from Barclays set a target price of $148.0 on 03/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.